{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4016","value":"10595"}]}],"title":"Week 0-24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5543","value":"15811"}]}],"title":"Week 24-52"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9027","value":"26406"}]}],"title":"Week 0-52"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"OG000","title":"OBINUTUZUMAB 1000MG and MMF"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic population included all patients randomized to and received any dose of obinutuzumab given as study medication.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 52","title":"Area Under the Plasma Concentration Versus Time Curve (AUC) of Obinutuzumab","type":"SECONDARY","unitOfMeasure":"ug/mL*day"}